Surgical Outcome Assessment of Gastrointestinal Malignancies: Opportunity Prediction by Sarcopenia on CT Measurement

Mercan, Umit; Akıncı, Melih; Cerit, Nurcan; Yılmaz, Kerim Bora; Seki, Ahmet; Hekįmoğlu, Baki

doi:10.1007/s12262-020-02198-8

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another retrospective study conducted in patients with earlystage colon cancer by Oh et al, the rate of sarcopenia was 27.8% and it was emphasized that sarcopenia increased postoperative complications after laparoscopic surgery. In another study, by Mercan et al, investigating the relationship between sarcopenia and surgical outcomes in patients with early-stage gastrointestinal malignancies, sarcopenia was reported as 37%, and it was found that sarcopenic patients performed poorly before and after surgery (12,14,15). Similarly, the rate of sarcopenia was found 25.7% in our study.…”

Section: Discussionsupporting

confidence: 76%

See 1 more Smart Citation

The Effect of Sarcopenia on Survival in Patients with Metastatic Colon Cancer

dogan¹,

Şahinli²,

zeynelgil³

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction: Sarcopenia is a common loss of muscle mass in cancer patients. Our aim in this study is to investigate the effect of sarcopenia on survival in patients with metastatic colon cancer. Material and Methods: The study was carried out retrospectively in patients diagnosed with metastatic colon cancer between January 2016 and December 2020. Sarcopenic patients were determined by total psoas area index and Hounsfield unit average calculation using computed tomography (CT) scan images obtained at the time of diagnosis. Results: A total of 70 patients with metastatic colon cancer were evaluated. Sarcopenia was detected in 18 patients (25.7%). The median age of sarcopenic patients was 72 (53-83) years. A significant correlation was found between age and sarcopenia (p=0.002). Median survival of sarcopenic patients was 11 months while non-sarcopenic patients had a median survival of 24 months. A difference was found in overall survival (OS) between the two groups (p=0.021). There was no difference in progression free survival (PFS) between sarcopenic and non-sarcopenic patients. Conclusions: In our study, a significant prognostic effect of sarcopenia on survival was found in patients with metastatic colon cancer. The survival of sarcopenic patients was poorer.

show abstract

Section: Discussionsupporting

confidence: 76%

“…Many studies have previously been conducted on the evaluation of sarcopenia in patients with gastrointestinal system tumors (11)(12)(13)(14)(15)(16)(17). Among these studies, there are also studies on early-stage colon cancer.…”

Section: Discussionmentioning

confidence: 99%